1077-94-7

Usage

Uses

Used in Pharmaceutical Industry:
5-Bromo-1H-indazole-3-carboxylic acid is used as a key intermediate in the synthesis of various pharmaceuticals for its ability to contribute to the development of novel compounds with therapeutic properties. Its unique structure allows for the creation of new drugs with potential applications in treating a range of diseases and conditions.
Used in Agrochemical Industry:
In the agrochemical sector, 5-Bromo-1H-indazole-3-carboxylic acid is utilized as a building block for the synthesis of new agrochemicals, including pesticides and herbicides. Its incorporation into these compounds can enhance their effectiveness in controlling pests and weeds, thereby improving crop yields and quality.
Used in Medicinal Chemistry Research:
5-Bromo-1H-indazole-3-carboxylic acid is employed as a research tool in medicinal chemistry for the exploration and development of new chemical entities. Its unique structural features make it a promising candidate for the design and synthesis of innovative therapeutic agents with improved efficacy and selectivity.
Used in Drug Discovery:
As a component in drug discovery processes, 5-Bromo-1H-indazole-3-carboxylic acid aids in the identification and optimization of lead compounds. Its presence in the molecular structure can influence the pharmacokinetic and pharmacodynamic properties of potential drug candidates, facilitating the development of more effective and safer medications.
Used in Chemical Synthesis:
5-Bromo-1H-indazole-3-carboxylic acid serves as a versatile building block in the synthesis of a wide range of organic compounds. Its reactivity and functional groups enable the formation of various chemical entities, including complex organic molecules and bioactive compounds, for applications in various industries.

InChI:InChI=1/C8H5BrN2O2/c9-4-1-2-6-5(3-4)7(8(12)13)11-10-6/h1-3H,(H,10,11)(H,12,13)

Upstream product

• 4498-67-3 1H-Indazole-3-carboxylic acid 
• 87-48-9 5-Bromo-1H-indole-2,3-dione 
• 16917-43-4 benzaldehyde 4-bromophenylhydrazone 

Downstream Products

• 53857-57-1 5-bromo-1H-indazole 
• 15719-64-9 methylammonium carbonate 
• 936132-61-5 5-bromo-3-formyl-indazole-1-carboxylic acid tert-butyl ester 
• 936132-62-6 3-(2-benzyloxycarbonylamino-2-methoxycarbonyl-vinyl)-5-bromo-indazole-1-carboxylic acid tert-butyl ester 
• 910904-74-4 C₁₈H₁₈BrN₃O₃ 

Relevant academic research and scientific papers

Heteroaromatic ring compound and application thereof

The invention relates to a heteroaromatic ring compound and application thereof. Specifically, the invention provides a compound shown as a formula I, or an optical isomer or raceme thereof, or a pharmaceutically acceptable salt thereof. The compound prov

5-HETEROARYL SUBSTITUTED INDAZOLE-3-CARBOXAMIDES AND PREPARATION AND USE THEREOF

Indazole compounds for treating various diseases and pathologies are disclosed. More particularly, the present disclosure concerns the use of an indazole compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., tendinopathy, dermatitis, psoriasis, morphea, ichthyosis, Raynaud's syndrome, Darier's disease, scleroderma, cancer, abnormal cellular proliferation, angiogenesis, Alzheimer's disease, lung disease, and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as neurological conditions/disorders/diseases linked to overexpression of DYRK1A.

INDAZOLE CONTAINING MACROCYCLES AND THERAPEUTIC USES THEREOF

Indazole macrocycle compounds of formula (I) for treating various diseases and pathologies are disclosed. More particularly, the present invention concerns the use of an indazole macrocycle compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, fibrotic disorders, bone or cartilage diseases, and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as genetic diseases and neurological conditions/disorders/diseases due to mutations or dysregulation of the Wnt pathway and/or of one or more of Wnt signaling components. Also provided are methods for treating Wnt-related disease states. Formula (I)

K-RAS MODULATORS WITH A VINYL SULFONAMIDE MOIETY

Provided herein are compounds comprising a vinyl sulfonamide moiety. Also provided herein are pharmaceutical compositions comprising such compounds, and methods of using such compounds and pharmaceutical compositions for inhibiting the post-translational

Synthetic method of 5-substituted indazole-3-carboxylic acid

The invention provides a synthesis method of 5-substituted indazole-3-carboxylic acid, and belongs to the field of pharmaceutical chemical synthesis, wherein R=hydrogen, alkyl, alkoxy, trifluoroalkoxyand halogen. A phenylhydrazine compound 3 is taken as a

METHODS OF USING INDAZOLE-3-CARBOXAMIDES AND THEIR USE AS WNT/B-CATENIN SIGNALING PATHWAY INHIBITORS

This disclosure features the use of one or more indazole-3-carboxamide compounds or salts or analogs thereof, in the treatment of one or more diseases or conditions independently selected from the group consisting of a tendinopathy, dermatitis, psoriasis, morphea, ichthyosis, Raynaud's syndrome, and Darier's disease; and/or for promoting wound healing. The methods include administering to a subject (e.g., a subject in need thereof) a therapeutically effective amount of one or more indazole-3-carboxamide compounds or salts or analogs thereof as described anywhere herein.

Indazol-carboxamide-pyridinone derivatives as well as preparation method and applications thereof

The invention belongs to the field of chemical medicine preparation, and concretely relates to indazol-carboxamide-pyridinone derivatives, a preparation method and applications thereof. The inventionprovides the indazol-carboxamide-pyridinone derivatives, and a structure is represented by a formula I. The present invention also provides the preparation method and the applications of the above indazol-carboxamide-pyridinone derivatives. The indazol-carboxamide-pyridinone derivatives provided by the invention are novel compounds obtained on the basis of a large number of screening, inhibit EZH2activity, and provide a novel selection for development and application of medicines for resisting tumors and autoimmune diseases.

5-SUBSTITUTED INDAZOLE-3-CARBOXAMIDES AND PREPARATION AND USE THEREOF

Indazole compounds for treating various diseases and pathologies are disclosed. More particularly, the present disclosure concerns the use of an indazole compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, Alzheimer's disease, lung disease, fibrotic disorders, cartilage (chondral) defects, and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, and neurological conditions/disorders/diseases linked to overexpression of DYRK1A.

ANTICANCER AGENT

An anticancer agent comprising a compound represented by the formula (I) [R1 represents hydrogen atom, hydroxyl group, a C1-6alkoxy group and the like; R2 and R3 represents hydrogen atom, a halogen atom, a C1-6alkyl group and the like; R4 represents hydrogen atom, a C1-6alkyl group, a C1-6alkylsulfonyl group and the like; R5 represents hydrogen atom or a substituent; .... represents a single bond or a double bond; R6 and R7 represents hydrogen atom, a C1-6alkyl group and the like; R8 represents hydrogen atom, a C1-6alkyl group and the like; A represents -O-, -S-, or - CH2-; D represents -C= or -N=; X represents methylene group, -O-, or -CO-; Q represents -N= or -C(R8)=; and Y represents a heterocyclic group or amino group], which shows a superior inhibitory activity against pim-1 kinase.

INDAZOLE-3-CARBOXAMIDES AND THEIR USE AS WNT/B-CATENIN SIGNALING PATHWAY INHIBITORS

lndazole-3-carboxamide compounds for treating various diseases and pathologies are disclosed. More particularly, the present disclosure concerns the use of an indazole-3- carboxamide compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as genetic diseases and neurological conditions/disorders/diseases due to mutations or dysregulation of the Wnt pathway and/or of one or more of Wnt signaling components. Also provided are methods for treating Wnt-related disease states.